Tag Archives: Hepatology

UTSW Residents Take Over DDW

Washington DC this past weekend was filled with residents from UTSW presenting their excellent work.

Current second-year residents Kristina Tzartzeva and Joseph Obi presented their research “Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis”. In this systematic review and meta-analysis, Drs Tzartzeva and Obi demonstrate the addition of AFP to ultrasound significantly increases the sensitivity for early HCC detection in patients with cirrhosis. This research was completed with Dr. Rich, a current GI fellow at UTSW, and the principal investigator Dr. Singal. Drs Parikh, Marrero, Yopp, and Waljee were also contributing authors on the study.

Second-year resident Ahana Sen presented her research “A Systematic Review of Failures Across the Colorectal Cancer Screening Process” in which she observes multiple causes for underuse and overuse and deviations from established guidelines for colorectal cancer screening. She postulates it would be possible to improve the effectiveness of CRC screening if these steps could be targeted. Dr Murphy was the principal investigator of this study, with significant contributions from Dr. Singal and Dr. Sigel.


Second-year resident Taylor Derousseau presented “Delayed Gastric Emptying in Pre-Lung Transplant Testing is Associated with Post-Transplant Acute Cellular Rejection Independent of Reflux”. In this study, Dr Derousseau retrospectively reviewed a database of prospectively collected data of patients undergoing lung transplant evaluation at UTSW. He finds an association with patients who had delayed gastric emptying also developing acute cellular rejection after lung transplant. Importantly, many of these patients with delayed gastric emptying were asymptomatic. Dr. Gavini was the principal investigator on this study, with contributions from Dr. Chan, Dr. Lo, and Dr. Kaza.


Komal DDW

Intern Komal Patel presented her work “Use of Fresh Frozen Plasma to Correct Coagulopathy in Patients with Variceal Bleeding” with Dr. Agrawal and Dr. Sarode. She retrospectively reviewed cases of patients who presented with  variceal hemorrhage to determine the effect of FFP on INR and outcomes, concluding this practice results in variable decreases in the INR and may be associated with rebleeding.


Lastly, third-year resident and rising Chief Resident Saroja Bangaru presented “Increased Use of Liver Transplantation as Therapeutic Option for Severe Alcoholic Hepatitis”. In this study, Dr. Bangaru surveyed transplant hepatologists about their practices and opinions with regards to liver transplantation in alcoholic hepatitis. Over half of respondents reported transplanting patients for severe AH, with excellent 1-year survival reported. Dr. Mufti was the principal investigator, with Dr. Pederson and Dr. Singal contributing to the work.


Help us congratulate our outstanding residents on their important work!


Answer to CC #16

Case challenge #16 presented a 19 yo white male hand tremors, new psychiatric disturbances, slurred speech, drooling, and difficulty walking. Work-up reveals imaging findings suggestive of cirrhosis. The test most likely to help reveal the diagnosis is CERULOPLASMIN for a diagnosis of Wilson’s Disease. 


92.5 percent of respondents got the correct answer – looks like we will have to find a tougher case next week! Take a look below for the common diagnostic tests for Wilson’s Disease, as well as the diagnostic criteria: 

Journal of Hepatology, March 2012, Vol.56(3):671685

Internal Medicine Journal Watch – April 2015

STRAIGHT FROM THE HOUSESTAFF – the April 2015 UT Southwestern Internal Medicine Journal Watch! They have summarized important issues in clinical practice, from alcoholic hepatitis to which medications to use for stroke prevention in afib. Make sure to take the EKG challenge at the end! You will have to view this post on our website to access the PDF.  There is a quick run down of the topics below:


  • Corticosteroids in severe alcoholic hepatitis after recent upper GI bleed. Dr. Jan Petrasek reviewing Rudler et al., J Hepatol. 2015 Apr;62(4):816-21. 10.1016/j.jhep.2014.11.003. Epub 2014 Nov 11.
  • Serum ammonia level for the evaluation of hepatic encephalopathy. Dr. Jan Petrasek reviewing Ge et al., JAMA. 2014 Aug 13;312(6):643-4.


  • Extended report: Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Dr. Brian Skaug reviewing Arts, et al. Ann Rheum Dis. 2015 Feb 17. pii: annrheumdis-2014-206879. doi: 10.1136/annrheumdis-2014-206879

Pulmonary/Critical Care

  • Trial of Early, Goal-Directed Resuscitation for Septic Shock [The Protocolised Management in Sepsis (ProMISe) Trial]. Dr. James Galloway reviewing Mouncey PR et al. N Engl J Med. 2015;372(14):1301-11.
  • A Randomized Trial of Icatibant in ACE-Inhibitor-Induced Angioedema. Dr. James Galloway reviewing Bas M, et al. N Engl J Med. 2015;372(5):418-25.


  • High-Sensitivity Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and Risk of Incident Heart Failure in Patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Dr. Natalia Rocha reviewing Bansal N, et al. JASN 2015; 26:946-956
  • Preoperative renin–angiotensin system inhibitors use linked to reduced acute kidney injury: a systematic review and meta-analysis. Dr. Natalia Rocha reviewing Cheungpasitporn W, et al. Nephrol. Dial. Transplant. 2015; doi: 10.1093/ndt/gfv023


  • Which drug should we use for stroke prevention in atrial fibrillation? Dr. Douglas Darden reviewing Lau, Yee C.; Lip, Gregory Y.H. Current Opinion in Cardiology. 2014 July 29 (4): 293-300.
  • EKG CHALLENGE: Contributed by Dr. Jeanney Lew

Screen Shot 2015-04-29 at 10.49.07 PM

All of the work above comes from the IMJW Editorial Board: Jan Petrasek, Brian Skaug, Ben Galloway, Natalia Rocha, Doug Darden, and Jeanney Lew!

Ascites – not just a cirrhosis thing…

At morning report this week, our residents and faculty had a great discussion on non-cirrhotic etiologies for portal hypertension and ascites. There is a great review article from Hepatology in 2011 by Schouten, et al, “Idiopathic Noncirrhotic Portal Hypertension”, which describes the different etiologies and how to evaluate patients with portal hypertension not due to cirrhosis. Also includes an extensive table of noncirrhotic causes of portal hypertension. Key points below from the article:

  • Worldwide, most common cause of noncirrhotic portal hypertension (NCPH) is schistosomiasis.
  • In Western countries, more common causes include intrahepatic and extrahepatic etiologies such as Budd-Chiari, primary biliary cirrhosis, PSC, congenital hepatic fibrosis, portal vein thrombosis, sarcoidosis, lymphoma compressing the portal vein.
  • However, if none of the diagnosis mentioned above is made for the patient, then consider idiopathic noncirrhotic portal hypertension (INCPH).
  • Proposed pathophysiology of INCPH:
    • Strong expression of inducible NO synthetase (iNOS) and endothelial NO synthetase (eNOS) in the sinus-lining of the cells leading to splenomegaly and increased splenic venous flow and portal hypertension
    • Obliteration of the portal venous microcirculation leading to increased intrahepatic resistance
  • Etiology of INCPH can be divided into 5 categories: chronic infection, exposure to toxins, thrombophilia, immunological disorders, and genetic disorders.
  • Most common immunosupressive medications associated with INCPH are thiopurines such as azathioprine and 6-mercaptopurine
  • Management: no current universal guidelines regarding GI bleed prophylaxis, anticoagulation for risk of thrombus, and liver transplantation with few case reports

Check out the article below!

Idiopathic Noncirrhotic Portal Hypertension

Internal Medicine Journal Watch – February 2015

STRAIGHT FROM THE HOUSESTAFF – the February 2015 Internal Medicine Journal Watch! They have summarized important issues in clinical practice, from Metformin in CKD to pre-exposure prophylaxis for HIV. There is even an EKG challenge at the end, if you are up for it! You will have to view this post on our website to access the PDF.  There is a quick run down of the topics below:


  • American Diabetes Association’s Standards of Medical Care in Diabetes – 2015.
    • Dr. Jeremy Warshauer reviewing Grant RW, et al. Diabetes Care 2015 Jan;38 Supplement 1
  • Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review
    • Dr. Nicolas Barros reviewing Inzucchi, SE, et al. JAMA 2014; 312(24):2668-2675


  • Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis
    • Dr. Brian Skaug reviewing Minier T, et al. Ann Rheum Dis 2014;73: 2087–2093

Healthcare Policy

  • Using drugs to discriminate – adverse selection in the insurance marketplace
    • Dr. Ashish Gupta reviewing Jacobs DB and Sommers BD. N Engl J Med. 2015 Jan 29;372(5):399-402

General Internal Medicine

  • Disorders of Plasma Sodium — Causes, Consequences, and Correction
    • Dr. Nicolas Barros reviewing Sterns, R, et al. NEJM 2015; 372:55-65
  • Acid–Base Problems in Diabetic Ketoacidosis
    • Dr. Nicolas Barros reviewing Kamel K, et al. NEJM 2015 ; 372:546-554

Platelet Transfusion

  • A Clinical Practice Guideline From the AABB
    • Dr. Nicolas Barros reviewing Kaufman RN, et al. Ann Intern Med. 2015 Feb 3;162(3):205-13


  • Association of Albumin-Creatinine Ratio and Cystatin C With Change in Ankle-Brachial Index: The Multi-Ethnic Study of Atherosclerosis (MESA)
    • Dr. Ben Jenny reviewing Garimella P, et al. Am J Kidney Dis. 2015;65(1):33-40

Infectious Disease

  • Tenofovir-Based Preexposure Prophylaxis for HIV Infection Among African Women
    • Dr. Brad Cutrell and Dr. Nicolas Barros reviewing Marrazzo J, et al. 2015; 372:509-518
  • Infectious Diseases Diagnosis and Treatment of C. difficile in Adults: Systematic Review
    • Dr. Brad Cutrell and Dr. Nicolas Barros reviewing Bagdasarian N, et al. JAMA 2015; 313(4):398-408


  • An interferon-free antiviral regimen for HCV after liver transplantation
    • Dr. Jan Petrasek reviewing Kwo et al., NEJM. 2014; Dec 18;371(25):2375-82
  • Decreasing Mortality Among Patients Hospitalized with Cirrhosis in the United States From 2002 through 2010
    • Dr. Jan Petrasek reviewing Schmidt et al., Gastroenterology. 2015 Jan 23.


  • Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents (DAPT trial)
    • Dr. Ben Jenny reviewing Mauri L, et al. N Engl J Med. 2014 Dec 4;371(23):2155-66.

EKG Challenge

  • Dr. Ben Jenny
  • Untitled
All of the work above comes from the IMJW Editorial Board (with Dr. Brad Cuttrell): Jan Petrasek, Purav Mody, Nicolas Barros, Ragisha Gopalakrishnan, Jeremy Warshauer, Shetal Patel,  Ben Jenny (not Jennings), Vishwanatha Lanka, Brian Skaug, Ashish Gupta, and Roma Mehta!

Acetaminophen Overdose

Summary points

  • Patients still die from acetaminophen poisoning because they are not recognised to be at risk of harm or present too late for effective treatment

  • Patients who are malnourished, have been fasting, take enzyme inducing drugs, or regularly drink alcohol to excess are at higher risk of liver damage

  • Treat patients who have ingested too much acetaminophen within eight hours of ingestion whenever possible

  • If the time of ingestion is known, treatment can be based on blood tests taken after four hours

  • If the timing is uncertain or unknown, treatment should be started immediately in all patients who are at potential risk

  • Treat patients as high risk unless factors that increase risk of harm are known to be absent


Factors that increase the risk of liver injury after an overdose of paracetamol

  • High chance of glutathione depletion: Malnourished (for example, not eating because of dental pain or fasting for more than a day), eating disorders (anorexia or bulimia), failure to thrive or cystic fibrosis in children, AIDS, cachexia, alcoholism

    • Clinical clues: history, low body mass index, urinalysis positive for ketones, low serum urea concentration

  • Hepatic enzyme induction: Long term treatment with enzyme inducing drugs, such as carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, rifabutin, efavirenz, nevirapine, and St John’s wort. Regular consumption of ethanol in excess of recommended amounts.

    • Clinical clues: history, abnormal liver function tests, increased international normalised ratio, increased γ-glutamyl transpeptidase

  • Abnormal renal or hepatic function at presentation


Rumack-Matthew Nomogram


N-acetylcysteine Dosing

NAC doses






(note: this post contains images – it is best to view this post on the actual website).

BMJ 2011;342:d2218

Implication of Gut Microbiota on Nonalcoholic Fatty Liver Disease

It is now well established that gut flora and chronic liver diseases are closely interrelated. This association is most evident at late stages of the disease: cirrhosis and impaired liver function are associated with intestinal bacterial overgrowth, small bowel dysmotility, increased gut permeability, and decreased immunological defenses, all of which promote bacterial translocation from the gut to the systemic circulation, leading to infections that in turn aggravate liver dysfunction in a vicious circle [1]. For a long time, the implication of gut flora in the pathophysiology of less advanced chronic liver diseases has been underestimated because technical limitations allow only for the culture of a small fraction of gut bacteria. Recent technological progress and next-generation DNA sequencing have allowed for more sophisticated analysis and sampling of the gut microbiota by culture-independent methods [2]. Thanks to these recent technological advances, knowledge about the role of gut microbiota disruption (dysbiosis) in gut diseases such as colon cancer, inflammatory bowel diseases, and irritable bowel syndrome has greatly increased, with possible new therapeutic strategies. More surprisingly, gut dysbiosis has been implicated in chronic metabolic disorders such as obesity, metabolic syndrome, diabetes, and cardiovascular diseases [3]. Nonalcoholic fatty liver disease (NAFLD) is the liver manifestation of the metabolic syndrome and thus evolves in the same context as these metabolic diseases [4]. It is therefore not surprising that recent literature emphasizes a potential role for gut dysbiosis in the pathophysiology of NAFLD.

NAFLD encompasses a spectrum of hepatic pathology (i.e., liver phenotypes). Accumulation of triglycerides in hepatocytes (hepatic steatosis) is the most common liver phenotype in NAFLD. Some individuals with hepatic steatosis develop nonalcoholic steatohepatitis (NASH), a more severe type of liver damage characterized by hepatic inflammation and liver cell death. In some individuals with the NASH phenotype, liver regeneration cannot keep pace with the increased rate of hepatocyte death, and liver scarring (fibrosis) ensues. Over time, some of these individuals accumulate sufficient fibrosis to develop cirrhosis. Because cirrhosis dramatically increases the risk for both primary liver cancer and overall liver-related mortality, liver cirrhosis is the NAFLD phenotype that has the worst prognosis. Epidemiologic studies indicate that NAFLD is now the most common cause of liver disease in many countries, including the United States [5]. It is estimated that at least 25% of American adults have some form of NAFLD, with about 6% of the general adult population having NASH and 2%–3% having NAFLD-related cirrhosis.

Human Association Studies Suggesting a Link between Gut Microbiota and NAFLD Severity

The first evidence that gut dysbiosis might be involved in NAFLD pathogenesis was provided by a few cross-sectional studies that evaluated the association between gut microbiota and the liver phenotype in NAFLD patients. Using quantitative polymerase chain reaction (qPCR) for selected bacteria in a small cohort of 50 patients (17 controls, 11 patients with hepatic steatosis, and 22 patients with NASH), Mouzaki et al. showed that NASH patients had decreased fecal Bacteroidetes and increased Clostridium coccoides [6]. The negative association between NASH and Bacteroidetes persisted after adjustment for body mass index (BMI) and daily fat intake.

Zhu et al. screened the whole gut microbiota using 16S ribosomal RNA pyrosequencing in a pediatric cohort of 63 children that included 16 healthy controls, 25 obese subjects without known liver disease, and 22 patients with biopsy-proven NASH [7]. They found that fecal species richness was diminished in obese subjects and NASH patients compared to controls. Most samples clustered by health status but not by age, gender, or ethnicity, indicating a specific connection between the liver phenotype and gut microbiome. At the phylum level, obese patients and NASH patients had a similar increase in Bacteroidetes and decrease in Firmicutes compared to controls. Proteobacteria exhibited a progressive increase from the control to the obese and the NASH groups and was the only phylum with a significant difference between obese and NASH patients. The decreased representation of Firmicutes in the obese and the NASH groups was mostly explained by a decreased abundance in two families: Lachnospiraceae and Ruminococcaceae, with the greatest reduction for Blautia and Faecalibacterium genera. The increase in Proteobacteria was mainly explained by an increased abundance of Enterobacteriaceae, especially Escherichia, which was the only abundant genus within the whole bacteria domain exhibiting a significant difference between the obese and the NASH groups. Interestingly, Escherichia are known alcohol-producing bacteria, and serum alcohol concentration was significantly higher in NASH patients compared to obese or control groups.

The Mouzaki and Zhu studies may seem quite conflicting, the first showing a decrease in Bacteroidetes and the second an increase. However, different populations were studied (adults versus children, controls: biopsy-proven steatosis versus obese patients without histology) using different approaches (qPCR versus pyrosequencing). Both works were also limited by small sample size. Thus, further studies including larger and well-characterized cohorts are required to better identify the associations between gut microbiota and the various liver phenotypes observed in NAFLD.

Animal Mechanistic Studies Demonstrating an Implication of Gut Microbiota in NAFLD

Cross-sectional studies allow for the discovery of potential associations between liver phenotype and certain gut bacteria, but they cannot establish a causal link. By using gut microbiota manipulations, recent animal studies have demonstrated direct roles for gut microbiota in each liver lesion observed in NAFLD: steatosis, NASH, fibrosis, and liver cancer.

Liver steatosis

Conventional C57BL/6J mice fed with a high-fat diet (HFD) for 16 weeks generally display liver steatosis, hyperglycemia, and systemic inflammation (responders), but some mice are nonresponders, developing no metabolic disorder with this dietary manipulation [8]. To explore the potential role of gut microbiota in these discrepant responses, gut microbiota from a responder or from a nonresponder mouse were transplanted into germ-free mice (i.e., responder or nonresponder-receivers) that were then fed a HFD for another 16 weeks. Despite similar weight gain, responder-receiver mice developed a higher level of liver steatosis, glycemia, and insulin resistance than nonresponder-receivers. These data support the concept that interindividual differences in the intestinal microbiome modulate the metabolic and hepatic consequences of high-fat-diet consumption. Potential mechanisms for enhanced liver steatosis were demonstrated in earlier studies. The intestinal microbiome can increase the efflux of free fatty acids to the liver by influencing intestinal expression of the lipoprotein lipase inhibitor Fiaf (fasting-induced adipose factor, also known as angiopoietin-like protein-4) [9, 10]). Colonic bacteria also ferment nondigestible carbohydrates to short-chain fatty acids (SCFAs). SCFAs have been proposed to contribute to obesity and liver steatosis as they provide approximately 10% of daily caloric consumption and may enhance nutrient absorption by promoting expression of glucagon-like peptide 2 [11, 12]. However, SCFAs also improve lipid and glucose metabolism and maintain intestinal homeostasis [11, 13]. Hence, the net effect of SCFAs on NAFLD pathogenesis remains unclear and is likely complex. For example, although total cecal SCFA concentrations of recipient mice given flora from responder versus nonresponder mice were similar in the Leroy study, two branched-chain fatty acids (isobutyrate and isovalerate) were significantly higher in responder-receiver mice. Branched-chain fatty acids, which can be de novo synthetized by several gut bacterial species, have been associated with insulin resistance and metabolic disease development [14].

Nonalcoholic steatohepatitis

Interindividual differences in the intestinal microbiome and severity of NASH, a more serious NAFLD phenotype, have also been linked. Targeted disruption of the NLRP3 or NLRP6 inflammasome altered the gut microbiota and was associated with enhanced colonic inflammation and NASH in mice fed methionine-choline-deficient-diets [15]. By studying several knockout models, the researchers discovered that more severe diet-induced NASH resulted from influx of intestinally derived toll-like receptor 4 (TLR4) and toll-like receptor 9 (TLR9) agonists into the portal circulation, which, in turn, activated tumor necrosis factor alpha (TNFα) in the liver. Wild-type mice that were cohoused with inflammasome-deficient mice also exhibited worsened NASH. Antibiotic treatment with ciprofloxacin and metronidazole reduced the severity of NASH in inflammasome-deficient mice and abolished transmission of the phenotype to wild-type animals, showing that gut microbiota drive NASH progression in this model. These findings have clinical relevance because human studies have demonstrated that NASH patients have greater endotoxemia and higher liver TNFα levels than patients with simple hepatic steatosis [1618]. However, endotoxemia does not seem to be an absolute requirement for NASH development, as it was absent in a majority of patients in another NASH cohort [19].

Liver fibrosis

Gut microbiota can also promote liver fibrosis, a known risk factor for NAFLD-related cirrhosis. In a recent study, mice fed a HFD before bile duct ligation (BDL) developed more severe liver fibrosis than control mice that were fed a standard chow diet before BDL [20]. HFD-related increases in liver fibrosis were associated with gut dysbiosis, especially an increase in Proteobacteria. To establish the causal link between the gut dysbiosis and worsened liver fibrosis, gut microbiota transplantation was performed before BDL. Control mice that received the gut microbiota from HFD mice demonstrated more severe liver fibrosis after BDL than HFD mice that were transplanted with gut microbiota from chow-fed mice. Selective transplantation of gram-negative or gram-positive bacteria showed that gram-negative bacteria were responsible for the observed enhancement of liver fibrosis.

Liver cancer

A recent study established a link between the gut microbiota and NAFLD-related hepatocellular carcinoma [21]. Neonatal mice were treated with a single application of the carcinogenic agent dimethylbenz(a)antracene and then fed a HFD or standard chow diet for 30 weeks. HFD-fed mice developed more hepatocellular carcinoma, and intestinal decontamination with antibiotics reduced liver cancer formation. Metabolomic analysis showed that HFD feeding increased deoxycholic acid, a secondary bile acid generated solely by gut bacterial strains that 7α-dehydroxylate primary bile acids (e.g., Clostridium cluster XI and XIVa). Oral antibiotics decreased deoxycholic acid levels in HFD-fed mice. Moreover, deoxycholic acid administration restored liver cancer development in HFD-fed mice despite concomitant treatment with antibiotics. These results demonstrate the importance of the gut microbiome in modulating bile acid homeostasis. However, the relationship between bile acids and severity of NAFLD is very complex, with deleterious or beneficial effects probably depending on the type of bile acid and/or the particular bile-acid-sensitive signaling pathway targeted. Bile acids are ligands for the farnesoid X receptor (FXR) and the G-protein-coupled receptor TGR5, both having been implicated in metabolic syndrome pathobiology [22, 23]. In a recent randomized double-blind placebo-controlled phase 2 clinical trial, obeticholic acid, a semisynthetic FXR agonist derived from the primary human bile acid chenodeoxycholic acid, significantly improved markers of liver inflammation and fibrosis in NAFLD patients with type 2 diabetes [24]. Thus, both harmful and beneficial hepatic effects of bile acids have been demonstrated in NAFLD, and further research is necessary to clarify the basis for the discrepant outcomes.

Gut Microbiota—Environment Interactions

There are thousands of bacterial species in the gut, and they all display an incredibly wide range of metabolic functions. Now that we realize that gut microbiota modulate NAFLD-related pathophysiology, the challenge is to decipher the mechanisms by which they exacerbate NAFLD severity [25]. As mentioned previously, gut microbiota could drive the severity of NAFLD through increased endogenous production of alcohol, activation of TLR signaling and TNFα production in the liver, or by altering the bile acid profile. Other potential mechanisms are emerging rapidly. For example, the intestinal microbiome seems to play an important role in regulating the availability of dietary choline, and choline deficiency is well-known to cause NASH with fibrosis in rodents [26]. A metabolomic study in C129S6 mice showed that feeding a HFD shifts the gut microbiota into a choline-degradation profile, resulting in low circulating levels of plasma phosphatidylcholine and high urinary excretion of methylamines [27]. The reduced bioavailability of choline in the HFD-fed mice mimicked the effect of choline-deficient diets that cause NAFLD. This information is clinically relevant because a recent human study demonstrated increased hepatic steatosis in 15 women who ate low-choline diets for 42 days [28]. Sequencing gut microbiota before the diet identified two classes of bacteria that predicted choline-deficiency-induced fatty liver: Firmicutes/Erysipelotrichi and Proteobacteria/Gammaproteobacteria. Interestingly, taking into account microbiota profile and the polymorphism of phosphatidyl ethanolamine N-methyltransferase (PEMT), which encodes an enzyme in the choline biosynthetic pathway, improved the prediction of liver steatosis occurrence. These findings demonstrate that host genetic background, diet, and the gut microbiota interact to influence NAFLD pathogenesis in humans, as is now known to occur in rodent models.

NAFLD is associated with a higher prevalence of gastro-oesophageal reflux [29] that requires treatment such as proton pump inhibitors or histamine receptor 2 antagonists. These antisecretory therapies have been associated with modifications in the gut microflora composition and increasing risk of enteric infections [30]. The significance of antisecretory-treatment-induced gut dysbiosis on the course and the severity of NAFLD remains to be determined.

In summary, NAFLD is an extremely common, complex disease that results from interactions between susceptible polygenic backgrounds and environmental factors. Recent evidence has introduced gut microbiota as a new crucial player in this complex story. Deciphering the mechanisms linking gut microbiota to NAFLD and its severity will advance understanding of the disease’s pathogenesis, thereby identifying new therapeutic targets that will ultimately improve the outcome in patients with this disease.


Boursier J, Diehl AM (2015) Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease. PLoS Pathog 11(1): e1004559. doi:10.1371/journal.ppat.1004559

Non-Alcoholic Fatty Liver Disease

See below for an excellent update on the presentation, pathophysiology, diagnosis, and management of non-alcoholic fatty liver disease, by Dr. Meredith Clary!


(A note to our email subscribers: this post includes a powerpoint presentation that is only available on the actual website – click the link above to access the full information of this post!)

Causes of an elevated serum Ferritin

The interpretation of an elevated serum ferritin requires consideration of several separate disease categories. These come under the broad headings of:

  • Iron overload
  • Acute inflammatory conditions
  • Liver disease
  • Alcohol excess
Causes of iron overload
  • Primary
    • Hereditary haemochromatosis
    • Hereditary aceruloplasminemia (Wilson’s disease)
  • Secondary
    • Transfusion overload
    • Excess dietary iron
    • Porphyria cutanea tarda
    • Ineffective erythropoiesis (Sideroblastic anaemia, Thalassemia)
  • Causes of high serum ferritin without iron overload
    • Liver disease – non-alcoholic
    • Hepatitic steatosis (NASH)* or viralhepatitis (B/C)
    • Alcohol excess
    • Bacterial infections
    • Fungal infections: i.e. Histoplasmosis
    • Hemophagocytic Syndrome
    • Thyrotoxicosis
    • Malignancy (especially haematological)
    • Chronic inflammatory conditions: rheumatoid arthritis, inflammatory bowel disease, etc.